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PCSK9 Inhibition
The Next Statin?*
Robert A. Vogel, MD
Denver, Colorado
Statins have been approved for the treatment of dyslipide-
mia for 25 years. This class has demonstrated substantial
and consistent reduction of cardiovascular events with an
acceptable safety profile. Despite the widespread use of
statins, patients continue to experience residual risk. To
date, attempts to reduce that risk with additional lipid
therapies have failed. Trials of niacin (AIM-HIGH
[Atherothrombosis Intervention in Metabolic Syndrome
with Low HDL/High Triglycerides: Impact on Global
Health] trial) and fenofibrate (ACCORD [Action to Con-
trol Cardiovascular Risk in Diabetes] trial) in subjects
already on statins have recently shown no further risk
reduction (1,2). Is statin therapy as good as it gets in
treating dyslipidemia? If not, what will be the next lipid
modifier with clinical benefit incremental to that of statins?
The answer may lie in understanding how statins work. By
inhibiting the rate-limiting step in hepatic cholesterol syn-
thesis, statins decrease intracellular cholesterol, resulting in
increased expression of hepatic low-density lipoprotein
(LDL) receptors and increased hepatic clearance of circu-
lating atherogenic particles including LDL. After delivering
their cargo of atherogenic lipoproteins for intracellular
degradation, most LDL receptors are recycled to the cell
surface.
See page 2344
Less well recognized is that statins increase the expression
of proprotein convertase subtilisin kexin 9 (PCSK9).
PCSK9 promotes hepatic LDL receptor degradation,
thereby reducing LDL receptor density and clearance of
LDL particles. This negative feedback response attenuates
statins’ lipid effects. Conversely, blocking PCSK9 might be
expected to increase the clearance of atherogenic lipopro-
teins and enhance the efficacy of statins. Thus, PCSK9
offers a novel approach to lipid management.
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observations. Abifadel et al. (3) first reported that a specific
heterozygous PCSK9 missense mutation caused autosomal
dominant hypercholesterolemia. Because loss of a single
allele is usually functionally inconsequential, a gain-of-
function mechanism was hypothesized. The second link was
that PCSK9 messenger ribonucleic acid levels were found to
be responsive to intracellular cholesterol (4). In the hepato-
cyte, PCSK9 undergoes obligatory autocatalytic cleavage,
but its catalytic activity is independent of its affinity for the
LDL receptor (5). This spatial and functional separation has
important pharmacological implications. PCSK9 binds to
the receptor and channels it internally toward the lysosomal
compartment for degradation. In doing so, it inhibits the
normal recycling of the LDL receptor back to the hepatic cell
surface. A third and perhaps most important clue was that
nonsense mutations in PCSK9 were associated with 15% to
30% reductions in LDL cholesterol, with significant reductions
in cardiovascular risk (6). These experiments of nature provide
plausibility to the hypothesis that pharmacologic interference
with PCSK9 can provide clinical benefit.
In this issue of the Journal, McKenney et al. (7) report the
results of a phase 2 trial of REGN727/SAR236553, a
human monoclonal antibody to PCSK9 in subjects with
LDL cholesterol 100 mg/dl on stable atorvastatin (10 to
40 mg) therapy. This trial randomized 183 subjects to 1 of
3 antibody doses or placebo administered subcutaneously
every 2 weeks or higher doses every 4 weeks for a total
treatment of 12 weeks. Both 2- and 4-week dosing resulted
in 40% to 72% and 43% to 48% reductions in LDL
cholesterol, respectively. Up to 9% increases in high-density
lipoprotein (HDL) cholesterol, 19% decreases in triglycer-
ides, and 29% decreases in lipoprotein(a) were observed.
Mild injection-site reactions were the most common ad-
verse events and 1 subject experienced leukocytoclastic
vasculitis, which was successfully treated with drug discon-
tinuation and steroid therapy.
This is a significant study, both because of the magnitude
of LDL reduction achieved and the novel pathway (PCSK9
inhibition) utilized. Important questions remain. What is the
extent of the unmet need for LDL reduction, not fulfilled by
optimal statin therapy? The few patients who are truly statin
intolerant might benefit from an alternative approach to
LDL reduction. However, PCSK9 inhibition probably
would be used as an adjunct to statin therapy. Maximum
doses of effective statins reduce LDL cholesterol up to about
60%, resulting in average serum levels of 70 to 80 mg/dl.
Existing statin studies suggest that cardiovascular risk con-
tinues to decrease with more intensive therapy, resulting in
lower LDL cholesterol levels (8). Because maximal statin
doses are infrequently prescribed, one might argue that
there is a greater need for clinicians to use higher, evidence-
based statin doses, especially for high-risk patients (9), than
to seek add-on therapy. However, neither goal is mutually
exclusive.
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June 19/26, 2012:2354–5 PCSK9 InhibitionIs a combination of PCSK9 plus statin therapy safe? We do
not know whether immune responses to fully humanized
PCSK9 antibody will develop after prolonged treatment.
The leukocytoclastic vasculitis observed in 1 subject may or
may not have been a consequence of therapy, as this
condition commonly occurs without drug initiation. Larger,
phase 3 trials are certainly needed. Equally important, what
are the consequences of very low LDL cholesterol that could be
achieved with combination therapy? We currently have no
clear safety concern for very low LDL cholesterol other than
possibly an increase in hemorrhagic stroke (10). It has,
however, taken 25 years of statin therapy to recognize their
association with memory loss and new onset diabetes,
recently acknowledged by the Food and Drug Administra-
tion (11).
Will patients be compliant with every 2- to 4-week admin-
istration of a subcutaneously administered drug, especially for an
symptomatic condition? About 50% of patients discontinue
tatin therapy within the first year. As mentioned previ-
usly, the affinity of PCSK9 for the LDL receptor is not
ependent on its enzymatic activity, making oral adminis-
ration of a small inhibitory molecule difficult. What orally
dministered drugs under investigation might supplant the need
or PCSK9 inhibition? At present, anacetrapib, a cholesterol
ster transfer protein inhibitor, has been shown to reduce
DL and increase HDL cholesterol by 40% and 138%,
espectively (12). Even if its HDL effect has little clinical
onsequence, it may prove to be an effective LDL cholesterol–
owering agent.
What are the theoretical advantages and disadvantages of
CSK9 inhibition compared with statins? Statins have myriad
leiotropic effects, including reducing inflammation, coag-
lation, and oxidation, all important antiatherogenic factors
13). There is considerable debate about the extent to which
hese effects contribute to the efficacy of statins, but they
robably play some role. PCSK9 inhibition probably will
ot share these effects. Conversely, maximally increasing
DL receptors may have synergistic advantages. By revers-
ng statin-induced PCSK9 up-regulation, PCSK9 inhibi-
ion increases the statin’s effectiveness on LDL cholesterol
owering. Moreover, LDL receptors contribute to the clear-
nce of atherogenic lipoproteins other than LDL, such as
ntermediate-density lipoproteins and remnant particles, the
atter via apolipoprotein E affinity. Increased intermediate-
ensity lipoproteins and remnant particle clearance may
ave real therapeutic benefit beyond that provided by LDL
eduction.Brown and Goldstein won a Nobel Prize for their
dentification of the LDL receptor in 1985 while they were
tudying familial hypercholesterolemia. The therapeutic tri-
mph of statins logically follows their pioneering efforts. So
ay PCSK9 inhibition (14).
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